Clinical Efficacy of Vedolizumab in the Treatment of Moderate-to-Severe Ulcerative Colitis and its Effect on Patients' Inflammatory Response and Intestinal Mucosal Barrier Function
Objective:To investigate the clinical efficacy of vedolizumab in the treatment of moderate to severe ulcerative colitis (UC) and its effects on patients' inflammatory response and intestinal mucosal barrier function.Methods:A total of 106 patients with moderate to severe UC treated in the department of gastroenterology of a hospital from August 2021 to December 2023 were selected and assigned to the control group and observation group by random number table method,with 53 patients in each group.The control group was treated with mesalazine enteric coated tablets,while the observation group was treated with vedolizumab for injection in addition to the treatment given in the control group.Intestinal barrier function indicators (D-lactic acid,diamine oxidase),inflammatory indicators[mucin 1 (MUC1),eosinophilic chemotactic factor (CCL11),tumor necrosis factor-α (TNF-α) and erythrocyte sedimentation rate (ESR)],Th17/Treg balance indicators (Th17,Treg and Th17/Treg),the time to disappearance of clinical symptoms (abdominal pain,diarrhoea,bloody purulent stool,rectal tenesmus),the time to normalization of ESR and C-reactive protein (CRP),clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,the levels of D-lactic acid,diamine oxidase,MUC1,CCL11,ESR and TNF-α were decreased in the both groups (P<0.05),with the observation group showing lower levels than the control group (P<0.05).Th17 and the Th17/Treg were decreased in the both groups (P<0.05),with the observation group showing lower levels than the control group (P<0.05).Treg was increased in the both groups (P<0.05),with the observation group showing higher levels than the control group (P<0.05).The time to disappearance of clinical symptoms such as abdominal pain,diarrhea,bloody purulent stool,rectal tenesmus and the time to normalization of ESR and CRP in the observation group was shorter than that in the control group (P<0.05).The total effective rate of the observation group (88.68％) was higher than that of the control group (73.58％,P<0.05).No statistically significant difference was observed in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion:Vedolizumab shows good clinical efficacy in the treatment of patients with moderate to severe UC,significantly promoting the resolution of clinical symptoms,improving intestinal mucosal barrier function,inhibiting inflammatory response,without increasing the risk of adverse reactions.
万方数据
维普
